Neuraxis Inc
NRXS3.900USD
+1.630+71.81%
Fechamento 05/20, 16:00（ET）Cotações atrasadas em 15 min
28.14MValor de mercado
PerdaP/L TTM
Mais detalhes de Neuraxis Inc Empresa
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Informações da empresa
Código da empresaNRXS
Nome da EmpresaNeuraxis Inc
Data de listagemAug 09, 2023
Fundado em2022
CEOMr. Brian Carrico
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 09
Endereço11611 N. Meridian St
CidadeCARMEL
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal46032
Telefone18126890791
Sitehttps://neuraxis.com/
Código da empresaNRXS
Data de listagemAug 09, 2023
Fundado em2022
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Ms. Beth Keyser
Ms. Beth Keyser
Independent Director
Independent Director
--
--
Mr. Gil Aharon
Mr. Gil Aharon
Director
Director
--
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
--
-100.00%
Mr. Bradley Mitch Watkins
Mr. Bradley Mitch Watkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1.11K%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sáb, 17 de mai
Tempo de atualização: sáb, 17 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Estatísticas dos acionistas
Acionista
Proporção
Brown (Christopher Robin)
10.99%
Hannasch (Brian)
10.75%
Creative Planning, Inc.
7.65%
Masimo Corp
7.37%
Parsons Capital Management, Inc.
1.62%
Other
61.63%
Tipo
Acionista
Proporção
Individual Investor
22.97%
Investment Advisor/Hedge Fund
8.74%
Corporation
7.37%
Investment Advisor
1.86%
Bank and Trust
1.48%
Hedge Fund
0.40%
Private Equity
0.28%
Other
56.92%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
30
4.17M
57.80%
+470.52K
2024Q4
29
4.04M
56.27%
+476.54K
2024Q3
28
3.89M
54.36%
+476.60K
2024Q2
27
3.62M
51.12%
+229.93K
2024Q1
18
1.89M
32.23%
+1.25M
2023Q4
18
2.14M
36.50%
+1.56M
2023Q3
14
2.07M
34.17%
+2.07M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Brown (Christopher Robin)
792.84K
10.99%
--
--
Jun 17, 2024
Hannasch (Brian)
682.90K
9.46%
+133.33K
+24.26%
Sep 30, 2024
Masimo Corp
531.55K
7.37%
--
--
Jun 17, 2024
Parsons Capital Management, Inc.
116.73K
1.62%
+103.73K
+797.89%
Dec 31, 2024
BMO Harris Bank N.A.
139.02K
1.93%
-10.00K
-6.71%
Dec 31, 2024
The Vanguard Group, Inc.
27.98K
0.39%
--
--
Dec 31, 2024
Citadel Advisors LLC
47.09K
0.65%
+47.09K
--
Dec 31, 2024
Stifel, Nicolaus & Company, Incorporated
25.71K
0.36%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
22.70K
0.31%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
